BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIVI BioVie Inc

Market Closed 07-24 16:00:00 EDT

1.37

-0.07

-4.86%

盘后1.37

+0.000.00%

17:38 EDT

High1.49	Low1.34	Vol112.04K
Open1.45	D1 Closing1.44	Amplitude10.42%
Mkt Cap10.24M	Tradable Cap10.20M	Total Shares7.48M
T/O156.97K	T/O Rate1.51%	Tradable Shares7.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIVI","market":"US","secType":"STK","nameCN":"BioVie Inc","latestPrice":1.37,"timestamp":1784923200000,"preClose":1.44,"halted":0,"volume":112042,"hourTrading":{"tag":"盘后","latestPrice":1.37,"preClose":1.37,"latestTime":"17:38 EDT","volume":66,"amount":89.89,"timestamp":1784929127658,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.048611111111111,"floatShares":7443300,"shares":7477100,"eps":-3.487337,"marketStatus":"Market Closed","change":-0.07,"latestTime":"07-24 16:00:00 EDT","open":1.45,"high":1.49,"low":1.34,"amount":156965.2623084,"amplitude":0.104167,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.487337,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.44,"preHourTrading":{"tag":"盘前","latestPrice":1.4579,"preClose":1.44,"latestTime":"08:40 EDT","volume":767,"amount":1091.4897812000002,"timestamp":1784896849794,"change":0.0179,"changeRate":0.012431,"amplitude":0.026319},"postHourTrading":{"tag":"盘后","latestPrice":1.37,"preClose":1.37,"latestTime":"17:38 EDT","volume":66,"amount":89.89,"timestamp":1784929127658,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4270667053320923,"impliedVol":1.6378,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BIVI","defaultTab":"news","newsList":[{"id":"2644034506","title":"BRIEF-Biovie Files To Offer Up To $300 Million In Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644034506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644034506?lang=en_us&edition=fundamental","pubTime":"2026-06-19 06:34","pubTimestamp":1781822058,"startTime":"0","endTime":"0","summary":"BRIEF-Biovie Files To Offer Up To $300 Million In Securities - SEC FilingJune 18 (Reuters) - BioVie Inc BIVI.O:BIOVIE - FILES TO OFFER UP TO $300 MILLION IN SECURITIES - SEC FILINGSource text: [ID:n0001520138-26-000244]Further company coverage: BIVI.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q137:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644803141","title":"BioVie Files $300 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2644803141","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644803141?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:46","pubTimestamp":1781819203,"startTime":"0","endTime":"0","summary":"BioVie  filed a shelf registration statement with the US Securities and Exchange Commission Thursday for the potential sale of up to $300 million of securities from time to time in one or more offerings.The filing covers class A common stock, preferred stock, warrants, debt securities, rights and units.The company intends to use the net proceeds for general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644903117","title":"BioVie files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2644903117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644903117?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:25","pubTimestamp":1781817909,"startTime":"0","endTime":"0","summary":"17:23 EDT BioVie (BIVI) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biovie-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biovie-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644532031","title":"BioVie - Files to Offer up to $300 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644532031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644532031?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:22","pubTimestamp":1781817725,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q137:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640694968","title":"BioVie posts corporate presentation spotlighting bezisterim longevity-focused therapy pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640694968","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640694968?lang=en_us&edition=fundamental","pubTime":"2026-06-02 22:20","pubTimestamp":1780410056,"startTime":"0","endTime":"0","summary":"BioVie highlighted bezisterim  as its lead oral small molecule, positioned as a TNFα modulator with CNS penetration.Topline data targeted for its Parkinson’s Phase 2b trial in Summer 2026; Long COVID exploratory Phase 2 readout targeted for late Summer 2026.Development plans hinge on financing, including an ascites Phase 3 launch and a new once-daily bezisterim Alzheimer’s Phase 3 program.Parkinson’s strategy emphasizes addressing motor symptoms alongside inflammation and insulin resistance, supported by earlier Phase 2 signals and preclinical data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL6q5670:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638229507","title":"BioVie to host live investor webinar with CEO presentation and Q&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2638229507","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638229507?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:03","pubTimestamp":1779883407,"startTime":"0","endTime":"0","summary":"BioVie will host a live investor webinar on June 2, 2026 at 4:15 p.m. ET.CEO Cuong Do is set to discuss bezisterim  development progress in neuroinflammatory diseases.Presentation also expected to cover BIV201, its late-stage program for refractory ascites, followed by a live Q&A.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL9f9PQv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139","IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","BIVI","LU2095319765.USD","SG9999014021.USD","BK4585","IE00BKPKM429.USD","SG9999014013.SGD","NDAQ","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4588","LU0314104364.USD","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638008865","title":"Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2638008865","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638008865?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:00","pubTimestamp":1779883200,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., May  27, 2026  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301871/0/en/Join-BioVie-s-Exclusive-Live-Investor-Webinar-and-Q-and-A-Session-on-June-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651264","title":"BioVie announces full enrollment of ADDRESS-LC trial of bezisterim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651264","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651264?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:32","pubTimestamp":1779798731,"startTime":"0","endTime":"0","summary":"BioVie (BIVI) announced full enrollment of the Company’s ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biovie-announces-full-enrollment-of-address-lc-trial-of-bezisterim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biovie-announces-full-enrollment-of-address-lc-trial-of-bezisterim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIVI","LC","BK4585","BK4166","LU2360107671.USD","LU1861217088.USD","BK4588","LU1861220207.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514595","title":"BioVie completes enrollment in Phase 2 long COVID trial of bezisterim, targets late summer 2026 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514595","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514595?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:06","pubTimestamp":1779797162,"startTime":"0","endTime":"0","summary":"BioVie completed enrollment in its Phase 2 ADDRESS-LC trial of bezisterim for neurological symptoms linked to long COVID.Topline results have not been presented; data are targeted for release in late summer 2026.The study is designed to evaluate whether bezisterim can ease disabling neurocognitive and neuropsychiatric symptoms; no FDA-approved treatments exist.Trial funding comes from a grant from the U.S. Department of War, reducing near-term development spending for the program.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLbzqMLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","BIVI","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","LU2095319765.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638117645","title":"BioVie Announces Full Enrollment of the Address-Lc Trial of Bezisterim for the Treatment of Neurological Symptoms Associated With Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2638117645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638117645?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA2FYFPH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638307514","title":"BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID","url":"https://stock-news.laohu8.com/highlight/detail?id=2638307514","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638307514?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"-Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May  26, 2026  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innov","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300996/0/en/BioVie-Announces-Full-Enrollment-of-the-ADDRESS-LC-Trial-of-Bezisterim-for-the-Treatment-of-Neurological-Symptoms-Associated-with-Long-COVID.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","LC","LU2360107671.USD","BK4588","BIVI","BK4166","LU1861220207.SGD","LU1861217088.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636207878","title":"BioVie Announces Completion of Phase 2 Sunrise-Pd Trial in Early-Stage Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2636207878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636207878?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA3QVFBD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073813","title":"BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073813","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073813?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105600,"startTime":"0","endTime":"0","summary":"Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026CARSON CITY, Nev., May  18, 2026  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3296537/0/en/BioVie-Announces-Completion-of-Phase-2-SUNRISE-PD-Trial-in-Early-Stage-Parkinson-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOL","BK4139","LU1169589451.USD","SSI","PD","BIVI","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258502","title":"BioVie Q3 FY26 net loss widens to $5.3 million; operating expenses climb to $5.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258502","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258502?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:57","pubTimestamp":1778533045,"startTime":"0","endTime":"0","summary":"BioVie posted a net loss of USD 5.3 million for the quarter ended March 31, 2026, widening from USD 2.8 million a year earlier.Operating expenses climbed to USD 5.4 million from USD 3 million, driven by R&D spending of USD 3.2 million and general and administrative costs of USD 2.2 million.R&D outlays rose as Sunrise PD Phase 2 costs increased to USD 2.06 million, while Long COVID Phase 2 costs were USD 2.65 million offset by USD 3.06 million of reimbursements.Cash and cash equivalents were USD 13.1 million at March 31, 2026, with working capital of USD 15.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analys","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7L5pJz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396168","title":"BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396168","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396168?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:00","pubTimestamp":1777291200,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., April  27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281541/0/en/BioVie-to-Host-Virtual-KOL-Event-to-Discuss-the-Phase-2-Study-of-Bezisterim-for-the-Treatment-of-Parkinson-s-Disease-ahead-of-Topline-Data-in-2Q26-on-May-7-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","KOL","BIVI","BK4181","BK4585","BK4588","BK4139","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627444513","title":"BioVie SUNRISE-PD bezisterim abstract accepted for presentation at 2026 AAN meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627444513","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627444513?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:05","pubTimestamp":1776168301,"startTime":"0","endTime":"0","summary":"BioVie disclosed acceptance of an abstract from its SUNRISE-PD study of bezisterim  in early Parkinson’s disease for presentation at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.Poster presentation is scheduled for April 20, covering baseline demographics and patient characteristics from enrolled participants.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLBYDGt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210149790.SGD","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2T93.GBP","BK4588","BK4139","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","LU0314104364.USD","BK4585","BK4112","BIVI","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547393","title":"BioVie publishes corporate presentation on bezisterim pipeline catalysts in Parkinson’s, Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547393?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:27","pubTimestamp":1775082433,"startTime":"0","endTime":"0","summary":"BioVie outlined late-stage clinical priorities for lead asset bezisterim, positioning Parkinson’s disease as near-term focus.Topline data from Parkinson’s Phase 2b trial expected in 2Q26.Exploratory Phase 2 study in Long COVID targets topline data in Summer ’26.Company plans to start Phase 3 program for ascites when funding becomes available.Next Alzheimer’s Phase 3 trial using once-daily bezisterim formulation planned upon securing funding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6Qds7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131074","title":"BioVie to present SUNRISE-PD bezisterim poster at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131074?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317108,"startTime":"0","endTime":"0","summary":"BioVie said an abstract from its SUNRISE-PD study will be presented at the AD/PD 2026 Advances in Science & Therapy annual meeting in Copenhagen, Denmark. The conference is scheduled for March 17-21, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL93sG1t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4585","BK4112","SG9999014005.SGD","SG9999014021.USD","BK4588","BK4139","NDAQ","LU2095319765.USD","LU2210149790.SGD","BIVI","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618317361","title":"BioVie Announces Abstract Accepted for Presentation at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618317361","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618317361?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., March  12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254576/0/en/BioVie-Announces-Abstract-Accepted-for-Presentation-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AD","PD","BIVI","BK4023","BK4132","LU1169589451.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613782834","title":"BioVie to Host Live Investor Webinar and Q&A Session with CEO Cuong Do","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782834","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782834?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:04","pubTimestamp":1771851857,"startTime":"0","endTime":"0","summary":"BioVie to Host Live Investor Webinar and Q&A Session with CEO Cuong Do               BioVie Inc. will host a live investor webinar and Q&A session on March 4, 2026 at 4:15 p.m. ET, featuring President","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL6bhBX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","LU2210150020.SGD","LU2095319765.USD","BIVI","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","BK4588","SG9999014039.USD","IE00B64PRP62.GBP","BK4139","BK4585","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioviepharma.com","stockEarnings":[{"period":"1week","weight":-0.2389},{"period":"1month","weight":-0.2865},{"period":"3month","weight":-0.0867},{"period":"6month","weight":0.123},{"period":"1year","weight":-0.8185},{"period":"ytd","weight":0.181}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.005325},{"month":2,"riseRate":0.5,"avgChangeRate":0.259645},{"month":3,"riseRate":0.625,"avgChangeRate":-0.036628},{"month":4,"riseRate":0.375,"avgChangeRate":0.025089},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.110348},{"month":6,"riseRate":0.555556,"avgChangeRate":0.426902},{"month":7,"riseRate":0.444444,"avgChangeRate":0.252223},{"month":8,"riseRate":0.25,"avgChangeRate":-0.209827},{"month":9,"riseRate":0.375,"avgChangeRate":-0.162595},{"month":10,"riseRate":0.375,"avgChangeRate":0.201324},{"month":11,"riseRate":0.5,"avgChangeRate":-0.005666},{"month":12,"riseRate":0.25,"avgChangeRate":-0.131533}],"exchange":"NASDAQ","name":"BioVie Inc","nameEN":"BioVie Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioVie Inc,BIVI,BioVie Inc股票,BioVie Inc股票老虎,BioVie Inc股票老虎国际,BioVie Inc行情,BioVie Inc股票行情,BioVie Inc股价,BioVie Inc股市,BioVie Inc股票价格,BioVie Inc股票交易,BioVie Inc股票购买,BioVie Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction